We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE ... who has a strong educational background in mathematics and computer sciences. His father, Henry B.R. Brown invented ...

Basal insulin therapy, currently administered either once or twice daily, is a well-established therapy for diabetes, providing a background ... as daily dosing with Novo Nordisk's Tresiba ...

Novo Nordisk is the global GLP-1 volume market ... and it will be effective in the 1st of January 2027. And just for background, the rough U.S. channel mix across our portfolio is about 50% ...

A patient advocacy group has started a campaign to stop Novo Nordisk from following through ... basal insulins – used to provide a background dose of insulin – are not always suitable for ...

Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will also ...

Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...

Compounded weight-loss medications such as those promoted in the Hims & Hers commercial aren’t approved by the Food and Drug Administration.

A major nonprofit hospital also faced blowback for buying an ad spot during the Super Bowl. NYU Langone ran a 30-second commercial featuring several of its physicians, including Dr. Howard Riina and ...

Despite strong Atlas growth, MongoDB must increase enterprise customer share to return to previous growth rates. See why I ...

Ancient DNA is telling us more and more about humans and environments long past. Could it also help rescue the future?